孙嘉璐,唐倩如,王海滨. 13价肺炎球菌多糖结合疫苗安全性的meta分析[J]. 实用预防医学, 2019, 26(7): 871-873.
SUN Jia-lu, TANG Qian-ru, WANG Hai-bin. Meta analysis on the safety of 13-valent pneumococcal polysaccharide conjugated vaccine. , 2019, 26(7): 871-873.
[1] 刘美蓉, 谭效锋, 陈哲. 肺炎链球菌实验室诊断方法的研究进展[J].河北医科大学学报,2016,37(2):235-239. [2] O'Brien KL, Wolfson LJ, Watt JP, et al. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years:global estimates[J].Lancet,2009,374(9693):893-902. [3] Rep MR.Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP)[J]. MMWR Recomm Rep,1997,46(RR-8):1-24. [4] Pneumococcal conjugate vaccine for childhood immunization-WHO position paper[J].Wkly Epidemiol Rec,2007,82(12):93-104. [5] 火文.13价肺炎球菌多糖结合疫苗在儿童中对社区获得性肺炎的早期影响[J].微生物学免疫学进展,2015,43(2):56-56. [6] Angoulvant F, Levy C, Grimprel E, et al. Early impact of 13-valent pneumococcal conjugate vaccine on community-acquired pneumonia in children[J].Clin Infect Dis,2014,58(7):918-924. [7] Kieninger DM, Kueper K, Steul K, et al. Safety, tolerability, and immunologic noninferiority of a 13-valent pneumococcal conjugate vaccine compared to a 7-valent pneumococcal conjugate vaccine given with routine pediatric vaccinations in Germany[J].Vaccine,2010,28(25):4192-4203. [8] Vanderkooi OG, Scheifele DW, Girgenti D, et al.Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine inhealthy infants and toddlers given with routine pediatric vaccinations in Canada[J].Pediatr Infect Dis J,2012,31(1):72. [9] Esposito S,Tansey S,Thompson A,et al.Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine compared to those of a 7-valent pneumococcal conjugate vaccine given as a three-doseseries with routine vaccines in healthy infants and toddlers[J].Clin Vaccine Immunol,2010,17(6):1017. [10] Bryant KA,Block SL,Baker SA,et al.Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine[J].Pediatrics,2010,125(5):866. [11] Robert W,Gurtman A,Rubino J,et al.Randomized,controlled trial of a 13-valent pneumococcal conjugate vaccine administered concomitantly with an influenza vaccine in healthy adults[J].Clin Vaccine Immunol,2012,19(8):1296. [12] Shiramoto M,Hanada R,Juergens C,et al.Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine compared to the 23-valent pneumococcal polysaccharide vaccine in elderly Japanese adults[J].Hum Vaccin Immunother,2015,11(9):2198-2206. [13] Amdekar YK,Lalwani SK,Bavdekar A,et al.Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in healthy infants and toddlers given with routine vaccines in India[J].Pediatr Infect Dis J,2013,32(5):509-516. [14] Huang LM,Lin TY,Juergens C.Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine given with routine pediatric vaccines in Taiwan[J].Vaccine,2012,30(12):2054-2059. [15] Sylvia H,Gurtman A,Hurley DC,et al.Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in infants and toddlers[J].Pediatrics,2010,126(3):e493. [16] Kim DS,Shin SH,Lee HJ,et al.Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine given to korean children receiving routine pediatric vaccines[J].Pediatr Infect Dis J,2013,32(3):266-273. [17] World Health Organization.Pneumococcal conjugate vaccine for childhood immunization-WHO position paper[J].Wkly Epidemiol Rec,2007,82(12):93-104. [18] 赵德峰,胡权,熊燕,等.武汉地区健康婴幼儿肺炎链球菌携带率及血清型分布[J].现代预防医学,2012,39(9):2166-2168. [19] 王铮.5岁以下儿童侵袭性肺炎链球菌病的血清型及耐药性分析[D].中国医科大学,2015. [20] 刘佳,王欣茹,赵志强,等.13价肺炎结合疫苗小鼠血清ELISA方法的建立与验证[J].中国新药杂志,2014(18):2144-2149.
2019, Vol. 26 
